Prevalence of problematic pharmaceutical opioid use in patients with chronic non-cancer pain: A systematic review and meta-analysis
- PMID: 39111346
- DOI: 10.1111/add.16616
Prevalence of problematic pharmaceutical opioid use in patients with chronic non-cancer pain: A systematic review and meta-analysis
Abstract
Background and aims: Chronic non-cancer pain (CNCP) is one of the most common causes of disability globally. Opioid prescribing to treat CNCP remains widespread, despite limited evidence of long-term clinical benefit and evidence of harm such as problematic pharmaceutical opioid use (POU) and overdose. The study aimed to measure the prevalence of POU in CNCP patients treated with opioid analgesics.
Method: A comprehensive systematic literature review and meta-analysis was undertaken using MEDLINE, Embase and PsycINFO databases from inception to 27 January 2021. We included studies from all settings with participants aged ≥ 12 with non-cancer pain of ≥ 3 months duration, treated with opioid analgesics. We excluded case-control studies, as they cannot be used to generate prevalence estimates. POU was defined using four categories: dependence and opioid use disorder (D&OUD), signs and symptoms of D&OUD (S&S), aberrant behaviour (AB) and at risk of D&OUD. We used a random-effects multi-level meta-analytical model. We evaluated inconsistency using the I2 statistic and explored heterogeneity using subgroup analyses and meta-regressions.
Results: A total of 148 studies were included with > 4.3 million participants; 1% of studies were classified as high risk of bias. The pooled prevalence was 9.3% [95% confidence interval (CI) = 5.7-14.8%; I2 = 99.9%] for D&OUD, 29.6% (95% CI = 22.1-38.3%, I2 = 99.3%) for S&S and 22% (95% CI = 17.4-27.3%, I2 = 99.8%) for AB. The prevalence of those at risk of D&OUD was 12.4% (95% CI = 4.3-30.7%, I2 = 99.6%). Prevalence was affected by study setting, study design and diagnostic tool. Due to the high heterogeneity, the findings should be interpreted with caution.
Conclusions: Problematic pharmaceutical opioid use appears to be common in chronic pain patients treated with opioid analgesics, with nearly one in 10 experiencing dependence and opioid use disorder, one in three showing signs and symptoms of dependence and opioid use disorder and one in five showing aberrant behaviour.
Keywords: Meta‐analysis; opioid analgesics; opioid dependence; opioid use disorder; prevalence; systematic review.
© 2024 The Author(s). Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Similar articles
-
Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD012509. doi: 10.1002/14651858.CD012509.pub2. Cochrane Database Syst Rev. 2017. PMID: 29084357 Free PMC article.
-
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.Cochrane Database Syst Rev. 2017 Apr 27;4(4):CD011983. doi: 10.1002/14651858.CD011983.pub2. Cochrane Database Syst Rev. 2017. PMID: 28447766 Free PMC article.
-
Heated tobacco products for smoking cessation and reducing smoking prevalence.Cochrane Database Syst Rev. 2022 Jan 6;1(1):CD013790. doi: 10.1002/14651858.CD013790.pub2. Cochrane Database Syst Rev. 2022. PMID: 34988969 Free PMC article.
-
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD009885. doi: 10.1002/14651858.CD009885.pub3. PMID: 26599576 Free PMC article. Updated.
-
Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.Cochrane Database Syst Rev. 2016 Mar 12;3(3):CD011565. doi: 10.1002/14651858.CD011565.pub2. Cochrane Database Syst Rev. 2016. PMID: 26968204 Free PMC article.
Cited by
-
A qualitative interview study exploring the experiences of pain specialists on prescribing opioids for chronic non-cancer pain.Sci Rep. 2025 Aug 13;15(1):29672. doi: 10.1038/s41598-025-15113-6. Sci Rep. 2025. PMID: 40804328 Free PMC article.
-
Chronic Pain and High-impact Chronic Pain in U.S. Adults, 2023.NCHS Data Brief. 2024 Oct;(518):CS355235. doi: 10.15620/cdc/169630. NCHS Data Brief. 2024. PMID: 39751180 Free PMC article.
-
Prescription of Strong Opioids in Chronic Non-Cancer Pain in the Province of Valladolid (Spain).Life (Basel). 2025 Jan 16;15(1):114. doi: 10.3390/life15010114. Life (Basel). 2025. PMID: 39860054 Free PMC article.
References
REFERENCES
-
- Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd‐Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211–1259.
-
- Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of chronic pain and high‐impact chronic pain among adults—United States, 2016. Morb Mortal Wkly Rep. 2018;67:1001–1006.
-
- Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta‐analysis of population studies. BMJ Open. 2016;6:e010364.
-
- Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al. Opioids for chronic noncancer pain: a systematic review and meta‐analysis. JAMA. 2018;320:2448–2460.
-
- Kalso E, Edwards JE, Moore AR, McQuay HJ. Opioids in chronic non‐cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical